Tenax Therapeutics Inc: 5%+ holders

As of November 6, 2026, 10 holders' latest Schedule 13D or 13G filings report owning 5% or more of Tenax Therapeutics Inc. The largest reported stake is ADAR1 Capital Management, LLC's, at 14%. 60 filings are on record since August 14, 2025 (Schedule 13G, September 8, 2026).

Who owns Tenax Therapeutics, Inc.?

Dellora Investments Master Fund LP also filed stake reports on 1 other company ↓

Sell to companies like Tenax Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-10-27 · Reporting person: BlackRock, Inc. · Sole voting: 2,754,990 · Shared voting: 0 · Sole dispositive: 2,804,788 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-27
• Filed 2026-10-15 · Holder: Millennium Management LLC · Percent: 3.6% · SCHEDULE 13G/A
• Filing 2026-10-13 · Reporting person: Sphera Funds Management Ltd. · Sole voting: 0 · Shared voting: 2,663,296 · Sole dispositive: 0 · Shared dispositive: 2,663,296 · SCHEDULE 13G/A, 2026-10-13
• Filing 2026-10-09 · Reporting person: Dellora Investments Master Fund LP · Sole voting: 0 · Shared voting: 2,061,000 · Sole dispositive: 0 · Shared dispositive: 2,061,000 · SCHEDULE 13G/A, 2026-10-09
• Filed 2026-09-11 · Holder: ING Groep N.V. · Percent: 0% · SCHEDULE 13G/A

Tenax Therapeutics Inc has 60 Schedule 13D or 13G filings on record since 2025-08-14. 10 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Tenax Therapeutics Inc and the warning signs.

See Tenax Therapeutics Inc's free Snapshot Watch Tenax Therapeutics Inc: email me the next time it files something

Free to see. No signup.

Keep reading

More on Tenax Therapeutics Inc and the records around it.

Tenax Therapeutics Inc elsewhere on the record

• Who owns it

Companies that share a holder

• Dellora Investments Master Fund LP also filed stake reports on 1 other company: Rezolute, Inc. (Aug 2026)
• ING Groep N.V. also filed stake reports on 1 other company: NEOGEN CORP (Dec 2025)
• Sphera Funds Management Ltd. also filed stake reports on 2 other companies: Outlook Therapeutics, Inc. (Feb 2026), ProMIS Neurosciences Inc. (Feb 2026)

Want the whole picture on Tenax Therapeutics Inc?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Tenax Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Tenax Therapeutics Inc covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   61 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Tenax Therapeutics Inc by CUSIP 88032L605 and gives its principal executive office as 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC 27517 (SCHEDULE 13G/A, 2026-10-27).

What the percentages are based on

Incorporated by reference to Item 11 of the cover page for each reporting person.Sphera Funds Management Ltd., SCHEDULE 13G/A, 2026-10-13

Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.Venrock Healthcare Capital Partners III, L.P., SCHEDULE 13G/A, 2026-08-14

Source of funds (Item 3)

This Schedule 13D/A is filed solely as a result of the increase in the number of issued and outstanding shares of the Issuer's Common Stock.Christopher Thomas Giordano, SCHEDULE 13D/A, 2026-07-31

Timeline

Swipe the table sideways to see every column.

Questions about who owns Tenax Therapeutics Inc

Who owns Tenax Therapeutics Inc?

On this page, 10 holders' latest ownership filings report 5% or more of Tenax Therapeutics Inc: ADAR1 Capital Management, LLC (14%, Schedule 13G, filed 2026-09-08), Janus Henderson Group Plc (9.99%, Schedule 13G, filed 2025-12-08), Bvf Partners L P (9.99%, Schedule 13G/A, filed 2026-08-14), Vestal Point Capital, LP (9.9%, Schedule 13G, filed 2025-11-14) and RTW Investments, LP (9.9%, Schedule 13G/A, filed 2026-08-14); 5 more are listed above.

Who are the largest shareholders of Tenax Therapeutics Inc?

By the share each holder's latest filing reports, the largest holders of Tenax Therapeutics Inc on this page are ADAR1 Capital Management, LLC (14%), Janus Henderson Group Plc (9.99%) and Bvf Partners L P (9.99%).

When did ADAR1 Capital Management, LLC buy into Tenax Therapeutics Inc?

The filings give report dates, not purchase dates. The earliest filing from ADAR1 Capital Management, LLC on this page is the Schedule 13G, filed 2026-09-08, reporting 14%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 60 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Tenax Therapeutics Inc

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Tenax Therapeutics Inc. With no account yet, you sign up free and land on the result.

• Get an alert when Tenax Therapeutics Inc is mentioned again
• Find former Tenax Therapeutics Inc employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes